Akums approves Q4 and FY26 results, recommends dividend, changes senior management
Akums Drugs & Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Board approved Q4 unaudited and FY26 audited standalone and consolidated results on May 14, 2026; auditor's opinion not modified, with a search and seizure emphasis of matter.
- Recommended final dividend of ₹1 per share and special dividend of ₹2 per share for FY26, subject to shareholder approval at the AGM.
- Appointed Mr. V Jagannathan as President – HR and ceased Mr. Arvind Srivastava as President – HR, both w.e.f. May 14, 2026; no reason stated.
Why it's rated major development: the year-on-year change is 46% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting For Financial Results
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Akums Drugs & Pharmaceuticals
- Acquisition / mergerMajor developmentAkums Drugs reports Q2 FY27 results and acquires Oriflame India's manufacturing business
- Financial resultsMajor developmentAkums Drugs board approves unaudited results for quarter ended 30 June 2026
- Financial resultsMajor developmentAkums Drugs approves June 2026 quarter results; consolidated tax demand of 560.8 million raised
- Dividend / buyback / bonusMajor development· Adverse for the businessAkums Q4 net profit ₹813.42 million vs ₹1,496.06 million; ₹3 dividend recommended
- Dividend / buyback / bonusMajor development· Adverse for the businessAkums Drugs approves FY 2026 results, appoints auditors, and announces dividends
Other other filings this fortnight
- Kesoram Industries gets Rs. 5,989.35 Lakhs arbitral award against Kesoram Textile Mills
- Sagar Cements receives no adverse observation letters for amalgamation scheme
- Kalpataru Projects International Ltd reports unaudited Q2 and H1 FY27 financial results
- Urja Global Ltd appoints new CEO and CFO, announces Q2 FY26 financial results
- Lloyds Enterprises Ltd reports unaudited financial results for Q2 FY 2026-27
- Urja Global Limited announces Q2 FY 2026-27 results and key managerial appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.